Allergy Diagnostics Market Size & Growth Analysis
According to recent insights, the global Allergy Diagnostics Market is gaining significant traction. It was valued at approximately USD 4.91 billion recently and is on a robust growth trajectory, expected to reach USD 13.68 billion by the end of the forecast period. This remarkable growth, estimated at a compound annual growth rate (CAGR) of 12.06%, can primarily be attributed to the increasing prevalence of allergies, heightened awareness about the importance of early diagnosis, and the ongoing enhancement of advanced diagnostic testing devices.
Market Drivers and Trends
The United States retains its position as the largest consumer of allergy diagnostics, benefitting from an established healthcare infrastructure, supportive reimbursement policies, and a favorable attitude towards in vitro diagnostic testing. Additionally, environmental factors, lifestyle changes, and heightened patient awareness are significant contributors to the rising demands from hospital labs, diagnostic centers, and research institutions.
Investments in research and development (R&D) are propelling forward with innovations in more sensitive testing kits and an expanding array of clinical applications that promise to reshape the market landscape.
Key Players in the Allergy Diagnostics Industry
Major players driving this market include:
- Thermo Fisher Scientific, known for products like ImmunoCAP and Phadia systems.
- DASIT Group SPA with its allergen-specific IgE tests.
- AESKU.GROUP GmbH's AESKU.DIA system and rapid test kits.
- Astellas Pharma, which provides treatments for allergic rhinitis.
- Epigenomics AG offering solutions like Epi proLung.
- Sun Pharmaceutical Industries and its oral antihistamine Ozel.
- Teva Pharmaceutical Industries Ltd. with products including Qnasl.
- Pfizer, Inc. known for Xolair.
- AbbVie, Inc. with treatments like Rinvoq.
- Lincoln Diagnostics providing various testing systems and allergen extracts.
Understanding Market Scope
The allergy diagnostics report details various attributes, including:
- Market Size in 2023: USD 4.91 billion
- Projected Size by 2032: USD 13.68 billion
- Growth Rate: CAGR of 12.06% from 2024 to 2032
- Base Year: 2023
- Forecast Period: 2024-2032
- Key Segments: By Type (Consumables, Instruments), Test Type (In Vivo, In Vitro), Allergen (Inhaled, Food, Drug), End-User (Hospitals, Diagnostic Labs)
Market Segment Insights
Type of Products
The consumables segment notably led the market in 2023. This includes reagents and test kits crucial for conducting tests, which guarantee recurring income due to their continuous demand in hospitals and labs. With the emergence of rapid and multiplex allergen panels, this segment is set to maintain its competitive edge, as companies innovate by enhancing kit sensitivity and precision.
Testing Methods
In vitro testing emerged as the market leader, holding 54.23% share in 2023. This method is known for measuring allergen-specific IgE levels effectively, serving a critical role amidst the rising instances of food allergies.
A growing number of individuals are diagnosed with allergies to common foods, further validating in vitro testing as the gold standard for accurate diagnosis.
Allergen Sources
Inhaled allergens accounted for 48.68% of market share in 2023, influenced heavily by the growing rates of respiratory allergies linked to industrialization and environmental pollution. This segment's growth further illustrates the impact of climate factors on allergy prevalence.
End-User Analysis
Hospital-based laboratories emerged as the leading end-user segment, capturing 32.65% share in 2023. Their role as primary healthcare providers for allergy victims, paired with increasing health insurance coverage, strengthens their significance in the market.
Regional Insights
North America dominated, accounting for 38.21% of the total market due to its advanced healthcare infrastructure and widely accepted insurance policies. In contrast, the Asia Pacific region is poised for the fastest growth, spurred by rising healthcare investments and growing public awareness regarding allergy-related diseases.
Recent Industry Developments
- March 2025 – Thermo Fisher Scientific unveiled a next-gen multiplex allergy testing platform.
- February 2025 – Siemens Healthineers introduced an AI-integrated allergy testing system.
- January 2025 – Eurofins Scientific added rapid home testing solutions to its repertoire.
- December 2024 – Omega Diagnostics formed a collaboration aimed at developing point-of-care testing kits.
- November 2024 – Hycor Biomedical received FDA clearance for its automated allergy testing system.
For complete insights and detailed market analysis, reach out directly for more information.
Frequently Asked Questions
What is the projected growth rate of the allergy diagnostics market?
The allergy diagnostics market is expected to grow at a CAGR of 12.06% from 2024 to 2032.
Which company is leading in allergy diagnostics?
Major players include Thermo Fisher Scientific, AESKU.GROUP, and Astellas Pharma among others.
What is the primary testing method used in allergy diagnostics?
In vitro testing is the leading method for measuring allergen-specific IgE levels.
What factors are driving the demand for allergy diagnostics?
Increasing prevalence of allergies, advancements in testing technology, and greater awareness about allergies.
Which regions are experiencing the fastest growth in allergy diagnostics?
The Asia Pacific region is expected to witness the highest growth due to increased healthcare expenditure and awareness.
